Filtered By:
Drug: Dexamethasone
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 6433 results found since Jan 2013.
Connexin 43 gap junction affects survival and drug resistance of multiple myeloma side population cells
J Physiol Pharmacol. 2023 Jun;74(3). doi: 10.26402/jpp.2023.3.10. Epub 2023 Aug 30.ABSTRACTDrug resistance remains a major challenge for multiple myeloma (MM) treatment, and side population (SP) cells may play a key role in this resistance. The function of connexin 43 (Cx43)-mediated gap junction intercellular communication (GJ-IC) in MM cells is poorly understood. Bone marrow mesenchymal stem cells (BMSCs) from different sources were isolated and cultured. SP cells of MM cell line RPMI 8266 were separated by flow cytometry. Real-time reverse transcriptase-polymerase chain reaction and Western blot were used to detect Cx43...
Source: J Physiol Pharmacol - September 3, 2023 Category: Drugs & Pharmacology Authors: Z Wang J X Fu X H Zhang Y Sun X P Ge Source Type: research
Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma
CONCLUSIONS: This semi-automated analysis was in high agreement with standard approaches for detecting response to MM therapy. This proof-of-concept study suggests that larger studies should be conducted to confirm how FDG PET analysis may aid early response detection in MM.PMID:37657154 | DOI:10.1016/j.tranon.2023.101767
Source: Translational Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Tyler J Wellman Sarah R Mudd Kelly N Godby Dustin W Wooten Jeremy A Ross Orlando F Bueno Danielle Wanik Chaitanya R Divgi Robert A Comley Luciano J Costa Jacob Y Hesterman Source Type: research
Rhabdovirus encoded glycoprotein induces and harnesses host antiviral autophagy for maintaining its compatible infection
Autophagy. 2023 Sep 1:1-20. doi: 10.1080/15548627.2023.2252273. Online ahead of print.ABSTRACTMacroautophagy/autophagy has been recognized as a central antiviral defense mechanism in plant, which involves complex interactions between viral proteins and host factors. Rhabdoviruses are single-stranded RNA viruses, and the infection causes serious harm to public health, livestock, and crop production. However, little is known about the role of autophagy in the defense against rhabdovirus infection by plant. In this work, we showed that Rice stripe mosaic cytorhabdovirus(RSMV) activated autophagy in plants and that autophagy s...
Source: Autophagy - September 1, 2023 Category: Cytology Authors: Xiuqin Huang Junkai Wang Siping Chen Siying Liu Zhanbiao Li Zhiyi Wang Biao Chen Chong Zhang Yifei Zhang Jinhui Wu Xiaorong Yang Qingjun Xie Faqiang Li Hong An Jilei Huang Huali Li Chuanhe Liu Xiaoxian Wu Ding Xiang Liu Xin Yang Guohui Zhou Tong Zhang Source Type: research
Houttuynia cordata Thunb repairs steroid-induced avascular necrosis of the femoral head through regulating NF- κB signaling pathway
In conclusion, our study demonstrated that HCT relieved SANFH, which might be possibly achieved by NF-κB pathway.PMID:37652100 | DOI:10.1016/j.toxicon.2023.107270
Source: Toxicon - August 31, 2023 Category: Toxicology Authors: Yuanyuan Wang Yaqi Zhan Chunxiao Ji Chunlei Shi Jie Han Source Type: research
Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis
CONCLUSIONS: While early treatment with moderate-dose dexamethasone or late treatment with high-dose dexamethasone may lead to the best effects for survival without BPD, the certainty of the evidence is low. There is insufficient evidence to guide this therapy with regard to plausible adverse long-term outcomes. Further RCTs with direct comparisons between systemic corticosteroid treatments are needed to determine the optimal treatment approach, and these studies should be adequately powered to evaluate survival without major neurosensory disability.PMID:37650547 | DOI:10.1002/14651858.CD013730.pub2
Source: Cochrane Database of Systematic Reviews - August 31, 2023 Category: General Medicine Authors: Susanne Hay Colleen Ovelman John Af Zupancic Lex W Doyle Wes Onland Menelaos Konstantinidis Prakeshkumar S Shah Roger Soll Source Type: research
Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature
CONCLUSIONS AND IMPORTANCE: ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.PMID:37644808 | DOI:10.1177/11206721231199120
Source: European Journal of Ophthalmology - August 30, 2023 Category: Opthalmology Authors: Martina Maceroni Angelo Maria Minnella Source Type: research
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research
